A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.
Oncolytic viruses (OVs) are promising anticancer agents but like other cancer monotherapies, the genetic heterogeneity of human malignancies can lead to treatment resistance. We used a virus/cell-based assay to screen diverse chemical libraries to identify small molecules that could act in synergy with OVs to destroy tumor cells that resist viral infection. Several molecules were identified that aid in viral oncolysis, enhancing virus replication and spread as much as 1,000-fold in tumor cells. One of these molecules we named virus-sensitizers 1 (VSe1), was found to target tumor innate immune response and could enhance OV efficacy in animal tumor models and within primary human tumor explants while remaining benign to normal tissues. We believe this is the first example of a virus/cell-based "pharmacoviral" screen aimed to identify small molecules that modulate cellular response to virus infection and enhance oncolytic virotherapy.
Diallo
Jean-Simon
JS
Ottawa Hospital Research Institute, Center for Cancer Therapeutics, Ottawa, Ontario, Canada.
Le Boeuf
Fabrice
F
Lai
Frances
F
Cox
Julie
J
Vaha-Koskela
Markus
M
Abdelbary
Hesham
H
MacTavish
Heather
H
Waite
Katherine
K
Falls
Theresa
T
Wang
Jenny
J
Brown
Ryan
R
Blanchard
Jan E
JE
Brown
Eric D
ED
Kirn
David H
DH
Hiscott
John
J
Atkins
Harry
H
Lichty
Brian D
BD
Bell
John C
JC
D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D050130:Oncolytic Virotherapy
Expert Opin Biol Ther. 2008 Sep;8(9):1381-91
18694356
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9578-83
15210966
Virology. 1997 Mar 3;229(1):77-89
9123880
Cancer Cell. 2003 Oct;4(4):263-75
14585354
Nat Rev Cancer. 2005 Dec;5(12):965-76
16294217
Nat Med. 2000 Jul;6(7):821-5
10888934
EMBO J. 2003 Jun 2;22(11):2552-60
12773372
Curr Gene Ther. 2009 Oct;9(5):341-55
19860649
J Biol Chem. 1977 Sep 25;252(18):6438-42
893418
Nature. 2009 Oct 8;461(7265):809-13
19812674
J Gen Virol. 2006 Nov;87(Pt 11):3379-3384
17030873
Mol Ther. 2008 Jan;16(1):52-9
17998900
Nat Rev Cancer. 2006 Jan;6(1):38-51
16397526
Nat Rev Immunol. 2008 Jul;8(7):559-68
18575461
Mol Cell. 2005 Jan 7;17(1):93-102
15629720
Head Neck. 2008 Aug;30(8):1045-51
18615711
Cancer Res. 2007 Mar 15;67(6):2857-64
17363609
J Virol Methods. 2008 Nov;153(2):276-9
18692525
J Cell Biol. 2002 Aug 5;158(3):395-9
12163463
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6
18815361
Curr Gene Ther. 2005 Dec;5(6):595-605
16457649
Cancer Res. 2003 Jan 15;63(2):348-53
12543787
Nat Rev Immunol. 2005 May;5(5):375-86
15864272
J Clin Invest. 2007 Nov;117(11):3350-8
17965776
Curr Cancer Drug Targets. 2007 Mar;7(2):157-67
17346107
Virology. 1996 Mar 1;217(1):76-87
8599238
J Dermatol Sci. 2008 Jun;50(3):185-96
18226503
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5893-5
7687056
J Virol. 2007 Feb;81(3):1479-91
17108037
Nat Rev Immunol. 2008 Aug;8(8):644-54
18654572
Mol Ther. 2005 Dec;12(6):1101-10
16140040